

1 **Topical application of Urolithin A slows intrinsic skin aging and protects from**
2 **UVB-mediated photodamage: Findings from Randomized Clinical Trials**

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

D'Amico D¹, Fouassier AM¹, Faitg J¹, Hennighausen N², Brandt M², Konstantopoulos D³,
Rinsch C¹, Singh A^{1†}

¹ Amazentis SA, EPFL Innovation Park, 1015 Lausanne, Switzerland

² SGS Proderm GmbH, Hamburg, Germany

³ Genevia Technologies OY, 33100 Tampere, Finland

†Correspondence: asingh@amazentis.com

24 Abstract

25 Urolithin A is a gut microbiome derived postbiotic that has been shown to stimulate mitophagy,
26 and improve muscle and mitochondrial health when administered orally to humans. In three
27 separate randomized trials, we have now investigated the effect of topical administration of
28 Urolithin A on skin aging features and on UVB-mediated photodamaged skin. Post-menopausal
29 women with evidence of skin aging such as > Grade 3 wrinkle formation were included in a
30 split-face/arm study design in the first trial (*aging study 1*; n=48), followed by a second larger
31 trial (*aging study 2*; n=108) in middle-aged men and women focusing on wrinkle reduction.
32 Healthy participants were included in the placebo-controlled, randomized UVB-induced trial
33 (*photo-damage trial*; n=22). Participants were randomized to receive topical supplementation
34 with either 0.5% Urolithin A cream or placebo for 8-weeks in a low-dose arm or 1% Urolithin A
35 cream or placebo in the high-dose arm in the *aging study 1*. In the *aging study 2* participants
36 were randomized to receive 1% UA in a day-cream, a night cream and a serum, that were
37 compared to the untreated site. For the *photo-damage trial*, topical patches containing either 0.5%
38 or 1% UA or placebo cream were applied for 24-hours following UVB irradiation. The primary
39 outcome in the *aging study 1* was an impact on biological pathways linked to skin aging in skin
40 biopsies, and an impact on skin barrier function after 8-weeks. Key secondary endpoints were a
41 change in facial wrinkle appearance (crow's feet area). The *aging study 2* focused on wrinkle
42 reduction as a primary outcome. In the UVB-mediated *photo-damage study*, the primary read-out
43 was the change in erythema after application. Molecular analyses were conducted on skin
44 biopsies and using *ex-vivo* systems to investigate the mechanism of action mediating skin
45 protective effects of Urolithin A. In the *aging study 1*, Urolithin A at 1% significantly up-
46 regulated collagen synthesis pathways in human skin biopsies and led to a decrease in wrinkle
47 depth on facial wrinkles. The lower dose had no significant impact. There was no change on skin
48 barrier function with both doses suggesting maintenance of a healthy skin barrier function. In
49 *aging study 2*, topical application of Urolithin A at the 1% dose in different formulations (day-
50 cream, night cream and serum) led to significant wrinkle reduction compared to the untreated
51 side, confirming the previous findings. Skin hydration was improved significantly as well. In the
52 third trial, investigating impact on photodamaged skin, Urolithin A application led to a
53 significant decrease in UV-induced erythema (~14%) compared to the untreated area, while

54 placebo and lower dose UA cream's showed no benefits. Urolithin A topical administration was
55 safe and well-tolerated in all studies. UA also inhibited collagen degrading and pro-
56 inflammatory pathways and up-regulated gene expression of biomarkers linked to induction of
57 mitophagy and autophagy in human skin cells. Taken together, these clinical studies support the
58 topical use of Urolithin A to manage and prolong skin health longevity by acting at the cellular
59 level, supporting collagen structure, reducing wrinkle appearance and protecting against
60 photoaging.

61

62 The studies are registered in clinicaltrials.gov as: NCT05300984; NCT05473832; NCT05300542

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82 Introduction

83 Skin is the largest organ in the body and serves key functions as a barrier against injuries, UV
84 light and pathogens. Chronological aging brings changes in skin appearance and a decline in its
85 protective functions. This is further accentuated following exposure to UV radiation, by a
86 process called photoaging¹. The most common signs of aging skin are the appearance of wrinkles,
87 skin thinning, hyperpigmentation, sagginess, and dryness. This derives from a combination of
88 biological changes, including a decline in quantity and quality of structural components of the
89 skin, such as collagen and elastin, as well as dysfunctions in cellular bioenergetics. Indeed, most
90 of the energy to support skin cell health is derived from mitochondria, making mitochondrial
91 dysfunction a key hallmark of skin aging^{2,3}. Finally, immune cells located in the skin are
92 impacted by the aging process. This reduces the ability of the skin to cope with excessive
93 inflammation by external agents and significantly contributes to the emergence of photoaging⁴.

94
95 Current approaches to counteract skin aging are limited and primarily include retinol or retinoid-
96 based solutions. They are effective, for example, at wrinkle reduction, but do not have the best
97 safety and tolerability profile and are controversial in the management of photoaging^{5,6}. There is
98 a need for new innovative natural bioactives for improving skin health and longevity, that have a
99 dual benefit profile, impacting both intrinsic and extrinsic aging, without irritations observed
100 with retinol and retinoids. Urolithin A (UA) is a food metabolite, and a postbiotic of the gut
101 microbiome that has been shown to both improve mitochondrial health and reduce age-
102 associated inflammation, i.e. inflamm-aging. UA increases mitophagy, the process of recycling
103 faulty mitochondria, and enhances biomarkers associated with better mitochondrial function in
104 several models of aging and age-associated conditions⁷. In humans, oral supplementation of UA
105 was shown to be safe, improve mitochondrial function, and improve muscle strength and
106 endurance in clinical studies in middle-aged and elderly subjects^{8,9}.

107
108 Topical application of UA represents a promising strategy to support skin health and extend skin
109 longevity through its combined effect on multiple hallmarks of skin aging. We performed a
110 systematic clinical investigation of the benefits of topical application of UA to investigate its
111 safety and impact on clinical readouts of both intrinsic skin aging and photoaging. Finally, we

112 analysed skin biopsies and human cell models to identify molecular mechanisms associated with
113 UA's protective effect on the skin tissue.

114

115

116

117

118 **Methods**

119 **Subject recruitment:** All the studies were approved by an independent institutional review
120 board (Institutional Review Board, proderm GmbH, Kiebitzweg 2, D-22869 Schenefeld,
121 Germany). The subjects were recruited at the study site for each of the studies (SGS Proderm,
122 Hamburg, Germany). The suitability of each subject was evaluated according to the various
123 inclusion and exclusion criteria. Subjects gave written informed consent to participate in the
124 study and to come to the scheduled visits. In the first aging study (*aging study 1*) only female
125 participants from 50 to 75 years of age with visible wrinkle in the face (grade 3 to 6 according to
126 wrinkle severity scale) were included. In the second aging study (*aging study 2*), both males and
127 females from 40 to 65 years of age were recruited with similar criteria as the first study. Subjects
128 had healthy skin in the test areas. Prior/concomitant diagnoses and prior/concomitant therapies
129 relevant for the study were recorded. Main exclusion criteria were any documented allergies to
130 cosmetic products and/or ingredients, skin care and/or skin cleansing products and use of any
131 topical medication at the test area within the last 3 days prior to the start of the study. For the
132 *photodamage study*, both females and male participants from 18 to 65 years of age were included.
133 Subjects had uniform skin color and no erythema or dark pigmentation in the test area prior to
134 the start of the study. The skin type of the enrolled subjects was classified by use of colorimetric
135 skin type classification.

136

137 **Randomization and instructions of use:**

138 The skin aging studies both followed the split-face study design, i.e., each participant was
139 randomly assigned to the test products to apply on either the left or the right side of the face and
140 arm in case of the first study where skin biopsies were collected. All studies were controlled,
141 randomized studies with the first aging and UVB erythema trial also being double-blind,
142 placebo-controlled studies. The second aging trial utilized a split-face design with a treated and
143 an untreated side for comparison. The tested products were the following for the both the *aging*
144 *study 1* and the photodamage study: a moisturizing skin base cream containing standardized
145 excipients (vehicle) and for the (active) arms containing either 0.5 or 1% UA (Mitopure™)
146 added in the base cream. The products tested in the *aging study 2* contained 1% UA (Mitopure™)
147 in a day-cream formulation, a night-cream formulation and a serum product. A study site
148 representative assigned test products so that both the subjects and the investigators were blinded
149 to the test article identification. The information containing the assignment of products to labels
150 was kept at the study site by a person not involved in the investigations and analysis of data
151 during the study. Statistical analyses plan was finalized before unblinding. Afterwards the
152 envelope with the assignment of codes to treatments was opened to unblind the study for analysis.
153 A study technician demonstrated to study participants the correct amount of the test product to be
154 applied during the first application. The test materials were applied twice daily in the morning
155 and evening for 8-weeks by the subjects at home according to the application training in the first
156 aging study, whereas in the second trial subjects applied it either in the day (for day-cream) or
157 the evening (for night-cream), or twice daily in the morning and evening for serum. The subjects
158 were instructed to use the test product every day.

159
160 **Skin barrier function** was quantified as transepidermal water loss (TEWL) and was measured
161 via a TEWAMETER® TM 300 (Courage & Khazaka, Cologne, Germany). TEWL is a non-
162 invasive method to measure the barrier function of the skin and is regarded as a sensitive
163 parameter to quantify skin barrier damage. One measurement per test area and assessment time
164 was recorded. Briefly, water evaporation from the skin was measured by placing cylindrical open
165 chamber with two hygrosensors at a defined distance from the skin. The probe was held in place

166 for each measurement for 30 seconds. The values of the last 10 seconds (= 10 values) were
167 averaged as the actual measurement value.

168
169 **Skin roughness and wrinkle assessment** was performed either via a DERMATOP blue (Eo
170 Tech SA, Marcoussis, France) *in aging study 2* or via standardized, computer-controlled facial
171 photography with a 24 Megapixel Nikon camera (Colorface®, Newton Technologies, Lyon,
172 France) *in aging study 1*. The anti-wrinkle efficacy of each treatment code was assessed in the
173 periorbital regions by investigating the three-dimensional structure of the wrinkles. These
174 assessments were conducted at 2 and 8 weeks in the first aging study and at 2, 4 and 8 weeks in
175 the second study. Using phase-shifted and gray-coded measurements of human skin the three-
176 dimensional surface structure of the investigated skin site was captured. The measuring principle
177 is based on digital fringe projection. The fringes that are projected under a defined triangulation
178 angle onto the surface of the measured target with a sinus-like intensity of brightness are
179 detected with a CCD camera. The three-dimensional skin surface profile is calculated from the
180 position of the fringes in combination with the gray values of each pixel. From the captured
181 three-dimensional structure, roughness parameters are calculated. Parameters: Rz and Ra are
182 chosen, representing mainly the rough structure (Rz) or the finer skin structure (Ra). A decrease
183 in the roughness parameters Rz and Ra corresponds to a decrease in the degree of skin roughness.
184 1 measurement per test area and assessment time was performed.

185
186 **Skin hydration assessment** was measured via the CORNEOMETER CM 825 (Courage &
187 Khazaka, Cologne, Germany). The measurement of stratum corneum hydration was performed
188 by the electrical capacitance method with the corneometer. The measuring principle is based on
189 changes in the capacitance of the measuring head, functioning as a capacitor. Between the
190 conductors consisting of gold, an electrical field is built. By these means, the dielectricity of the
191 upper skin layer is measured. Because the dielectricity varies as a function of the skin's water
192 content, the stratum corneum hydration can be measured. Five measurements per test area and
193 assessment time were performed and the average recording used for statistical analysis.

194
195 **Skin biopsy excision (from aging study 1)**: The room and biopsy area (dorsal forearms) were
196 disinfected prior to the procedure with the disinfectant spray (e.g. Octenisept®). A local

197 anesthetic (e.g. Skandicain® 1%) was administered to the biopsy site subcutaneously using a
198 sterile syringe, fitted with a suitable sterile needle, to the biopsy area prior to excision of the
199 biopsy. Punch biopsies (3-mm) were be sampled by a physician using a punch biopsy instrument.
200 The biopsy specimen contained the epidermis and the dermis. Each biopsy sample was then
201 appropriately labelled (with the study and subject number). Following the biopsy excision, the
202 wound was closed with SteriStrips® and covered with a protective dressing. The subjects were
203 supplied with waterproof dressings for covering the wounds after skin biopsies were taken. The
204 wounds had to be kept dry until the wounds healed. Instructions on changing the dressing and
205 spare dressings were provided to the subjects. In order to reduce the risk of hyperpigmentation
206 the participant's undergoing skin biopsy procedure were instructed to avoid sunlight at the test
207 areas after conduct of the study and/or to use a sun protection cream. Biopsies were collected at
208 baseline and end of the study.

209

210 **MED dose calculation, UVB erythema induction and assessments:** A solar simulator
211 multiport 300 W (SOLAR Light Co, Philadelphia, USA) lamp equipped with appropriate
212 filtration was used to irradiate the skin test areas with the requested irradiation intensity on spots
213 with a diameter of 1 cm. A single irradiation per test area was performed. Test areas were
214 outlined with a skin marker on the backs of the subjects. Thereafter, baseline measurements were
215 performed on all test areas. After that six spots for minimal erythema dose (MED) determination
216 were irradiated on the back with a diameter of 0.9 cm each. The UVB dose was increased from
217 spot to spot by an increment of 25 %. An untreated irradiated control area served as a negative
218 control. After irradiation, the test products were applied using an occlusive patch to the irradiated
219 spots post irradiation. 23 ± 2 hours after irradiation, subjects returned to the study site and
220 product topical patches were removed. Residues of the test products were carefully removed with
221 a dry soft paper tissue. The MED dose and a change in skin redness (erythema score) from
222 baseline was recorded via a CHROMAMETER CR 400 (Minolta, Device D-Langenhagen,
223 Germany). The Chromameter defines the measured color in the $L^*a^*b^*$ color coordinate system.
224 The L^* -value defines the brightness. The color is defined by the parameters a^* (red-green axis;
225 negative a^* -value green, positive a^* -value red) and b^* (blue-yellow axis, negative b^* -value blue,
226 positive b^* -value yellow). The a^* value correlates well with visual assessments of skin redness
227 (erythema). a^* is a measure for erythema. An increase in the a^* -value corresponds to an increase

228 in the degree of skin redness. A trained grader also assessed the skin erythema for each group of
229 irradiation dose of the different test areas, according to the following scale: -2=marked increase
230 in redness compared to negative control (untreated); -1 =slight increase in redness compared
231 to negative control (untreated); 0=no difference in redness compared to negative control
232 (untreated) (no effect); 1=slight decrease in redness compared to negative control (untreated);
233 2=marked decrease in redness compared to negative control (untreated); 3=complete suppression
234 of redness.

235

236 **Adverse reactions recording:** All ICH GCP guidelines of recording of adverse reactions (ARs)
237 were followed. For all the clinical studies all ARs were assessed by the study physician for a
238 causal relationship between the test material and the adverse event (AE) was established. All
239 adverse reactions (excluding those parameters being scored as part of the protocol) were
240 documented in the study records. ARs were recorded from study enrolment of the subject in a
241 study to until 5 days following last administration of test product.

242

243 **RNA-seq**

244 Skin tissue samples were disrupted in a TissueLyser and RNA extraction performed using an
245 automated QiaSymphony extraction robot and the QIAsymphony RNA Kit. Strand-specific
246 cDNA library preparation was performed by purification of poly-A containing mRNA molecules,
247 mRNA fragmentation, random primed cDNA synthesis (strand-specific), adapter ligation and
248 adapter specific PCR amplification. RNA-seq run was performed using the NovaSeq6000 using
249 S4 flowcells with 2x150bp. Quality Control (QC) and preprocessing of raw reads was performed
250 by an in-house QC pipeline. The pipeline utilizes fastP version 0.23.2 [Chen, 2018], for quality
251 control, quality trimming, and adapter clipping procedures. Reads with a minimum PHRED
252 score of 15, a minimum length of 15 bp, and a minimum unqualified percent limit of 40 (40%)
253 were retained for downstream analysis. QC reports were summarized by MultiQC version 1.12
254 [Ewels et al., 2016]. Quality-processed read pairs were mapped against the Ensembl human
255 reference genome GRCh38.99, using a transcriptome annotation GTF file (version GRCh38.105).
256 In particular, an in-house RNA-sequencing alignment pipeline that utilizes the STAR algorithm
257 version 2.6.1c [Dobin et al., 2013] was applied. Read counting was performed on the gene-level,

258 using htseq-count [Putri, 2022]. To inspect the alignment results, MultiQC was used accordingly.
259 Read counts were normalized to account for inherent compositional and technical biases using
260 “median of ratios” [Anders and Huber, 2010] method from DESeq2 R package [Love, 2014].
261 Differential expression analysis was applied for Mitopure condition, controlling by vehicle
262 condition, and by comparing samples between two visits (T2 vs T1), adjusting the DESeq2
263 design formula accordingly (design = ~ Treatment + visit + Treatment: visit). Before DEA, a
264 pre-filtering step was applied to remove low abundance mRNA measurements, by excluding
265 genes with less than 10 total counts across samples. Additionally, an independent filtering
266 procedure of DESeq2 was enabled, to filter out genes with very low counts that are unlikely to
267 show significant alterations in gene expression. Gene symbols (HGNC nomenclature),
268 descriptions, and biotypes were matched to Ensembl GTF ids by using the R package biomaRt. v.
269 2.46.3 [Durinck et al., 2009]. P-values were corrected for multiple-testing using the Benjamini
270 and Hochberg (BH) method [Benjamini and Hochberg, 1995].

271

272 **Gene Set Enrichment Analysis**

273 Gene Set Enrichment Analysis (GSEA) ¹⁰ was performed by using the R package ClusterProfiler
274 ¹¹. All processed and filtered genes (genes with at least 10 total counts across samples having an
275 applicable p-adjusted value) were ranked by the comparison’s log2 fold change, and the
276 enrichment of a given gene set among “activated”- or-“suppressed” genes was statistically tested.
277 Gene sets from ontologies within Gene Ontology (GO) ¹² Biological Processes (BPs) were
278 tested. The minimum and maximum gene set sizes were set to 10 and 500, respectively. The
279 resulting p-values were adjusted using the BH method. Enriched terms with a maximum adjusted
280 p-value of 0.05 were considered statistically significant. GSEA significant results were
281 visualized as dot plots using the enrichplot R package ¹¹. Expression changes of core enrichment
282 genes of significant GO BP terms for the “Mitopure normalized over vehicle” comparison was
283 further visualized. For the particular analysis, only subjects present in both visits (T1 and T2)
284 and both treatments (Mitopure and vehicle) were considered. Initially, for each treatment, each
285 subject’s T2 expression values were corrected by their corresponding T1 expression. Then,
286 Mitopure expression changes were further corrected by the vehicle expression changes, between
287 the respective subjects. Ratios are referred as “Fold changes over vehicle”. Finally, log2 Fold

288 changes over vehicle were visualized as heatmaps, by utilizing pheatmap R package [Kolde,
289 2018]. Genes were hierarchically clustered with a euclidean distance metric using complete
290 linkage.

291

292 **Skin aging dataset analysis**

293 A text file depicting gene expression changes with age in skin was retrieved by the supplemental
294 material of a previously published study¹³. The particular dataset was reanalyzed by GSEA as
295 described above, adjusting “Beta” value which was considered a ranking factor instead of log2
296 Fold Change. Significant suppressed GO BP terms were intersected with the corresponding
297 significant activated GSEA results of “Mitopure normalized over vehicle” comparison, resulting
298 to one common BP term, “Collagen Fibril Organization”. Common core enrichment genes
299 between the two instances of the particular term were further processed, and visualized as
300 follows: (a) For the RNA-seq dataset, bar plots of “Fold changes over vehicle” (see above for
301 definition) were plotted, while (b) the aging dataset was visualized as bar plots of Beta values.

302

303 **Quantitative real-time PCR (q-RT-QPCR)**

304 RNA from cells and reconstituted epidermis was extracted using TRIzol (Thermo Scientific,
305 15596026) and then transcribed to cDNA by the QuantiTect Reverse Transcription Kit (Qiagen,
306 205313) following the manufacturer’s instructions. The q-RT-PCR reactions were performed
307 using the TaqPath ProAmp master mix (Applied biosystems, A30866) and the expression of
308 selected genes was analysed using the Quantstudio 6 flex (Life technologies) and following
309 TaqMan probes listed in Supplementary table 3. All quantitative polymerase chain reaction (PCR)
310 results were presented relative to the mean of housekeeping genes ($\Delta\Delta C_t$ method). mRNA levels
311 were normalized over RPLP2 for gene expression for cell and tissue samples.

312

313 **Reconstituted human epidermis**

314 Ten-day-old reconstructed human epidermis (RHE; batch 01015-587) were placed in proprietary
315 maintenance medium (Bioalternatives). Topical application with a moisturizing cream with or
316 without Mitopure at 1% was performed for 24 hours. The RHE were then rinsed in PBS and
317 irradiated with UVB (+UVA) - 850 mJ/cm² (+ 6 J/cm²) using a SOL500 Sun Simulator equipped

318 with an H2 filter (Dr. Hönle, AG). After irradiation, the treatments were renewed and the RHE
319 incubated for 24 hours. In parallel, non-irradiated conditions were performed and kept in the dark
320 during the irradiation time. PGE2 released in the culture supernatants was measured using a
321 specific ELISA kit according to the supplier's instructions (Enzo Life Sciences, ADI-900-001).
322 All experimental conditions were performed in n=3.

323

324 **Statistical analysis**

325 The mean values of raw data and calculated values were presented in bar charts with 95 %
326 confidence limits for each treatment and assessment time. A significance level of 0.05 (alpha)
327 was chosen for statistical analysis. Due to the proof-of-concept character of the study, no
328 adjustment for multiplicity was done. Pairwise comparison of treatments was done by paired t-
329 test on differences to baseline for each assessment time and treatment group. For visual and
330 imaging data pairwise comparison of treatments was done by Wilcoxon signed rank test on raw
331 data. The computation of the statistical data was carried out with commercially available
332 statistics software (SAS for Windows).

333

334

335

336

337

338

339

340

341

342

343

344 **Results**

345 Demographics

346 For the *aging study 1*, a total of 55 participants were screened in the placebo-controlled, first
347 aging study. Of them, n=48 middle aged women subject with mean age of 58.6 ± 6.6 years were
348 randomized (Figure 1) in to two study arms with a split-face/arm study design with a lower dose
349 active group compared to placebo and a second higher dose active group compared to placebo.
350 All participants completed the trial and there were no dropouts. Ethnicity of all participants was
351 Caucasian. In the *aging study 2*, n=108 middle-aged subjects with a mean age of 55.4 ± 6.6 years
352 were randomized using a split face study design with a treatment side compared to an untreated
353 side. All subjects completed the study protocol (Supplementary Figure 1A). There were 29 males
354 (27 %) and 79 females (73 %) in the final analysis of which n=2 (2 %) were Black, 93 (86 %) were
355 Caucasian, n=3 (3 %) East Asian, n=3 (3 %) Hispanic and n=7 (6 %) West Asian ethnicity.
356 In the UVB-mediated erythema trial (placebo-controlled, Photo-damage study), n=22 subjects
357 (10 male (48 %), 11 female (52 %) with mean age 44.0 ± 14.1 years and Caucasian ethnicity)
358 were enrolled. There was one drop-out subject and n=21 subjects completed the study protocol
359 (Supplementary Figure 1B).

360

361 Safety

362 In the *aging study 1*, no adverse reactions with any relationship to study products were reported
363 by any subject. In the *aging study 2*, four adverse reactions occurred across three subjects as
364 varying forms of skin irritation, including erythema, papules, itching and burning. Of the adverse
365 reactions documented during the conduct of this study, all were classified as being of mild
366 severity (Supplementary Table 1). In all cases, subjects remained in the study and recovered
367 without sequelae. In the *photodamage trial*, two adverse reactions occurred in the form of skin
368 irritation with erythema in one subject. The reactions were of mild severity and resolved without
369 sequelae.

370

371 Wrinkle reduction with 1% topical UA application

372 In the *aging study 1*, wrinkle reduction was measured after 2, and 8-weeks of test treatment
373 application (Fig. 2A). The UA 1% treatment group showed a significant reduction in wrinkle
374 depth at 8-weeks ($p=0.04$; Figure 2B) compared to the placebo treated side. UA at 0.5% did not
375 showed any significant effect compared to the Placebo (Supplementary Table 2). In the *aging*
376 *study 2*, UA at 1% was found to have a significant impact on reducing wrinkles (finer and
377 rougher skin structures computed as Ra and Rz, respectively) with the effect already manifesting
378 after 2 weeks of application and maintained with 4 and 8-weeks of application, compared to the
379 untreated side (Supplementary Table 2). The effect was independent of timing of application and
380 matrix of the product applied, as the three products (day cream, night cream and serum)
381 containing 1% UA showed similar wrinkle reducing benefits (Figure 2C, day-cream; Figure 2D,
382 night-cream; data for serum are shown in Supplementary Table 3).

383

384 Impact on Skin barrier and skin hydration

385 All subjects entering the skin aging studies had a healthy skin barrier and topical UA application
386 showed no negative impact on skin barrier, with function remaining unchanged(Figure 2D).
387 Daily application of the creams (day, night creams and serum) containing 1% UA significantly
388 improved skin hydration after 2-weeks of use in comparison to pre-test treatment level. The
389 observed improved skin hydration levels, as measured by skin capacitance, were maintained also
390 after 8 weeks of application in comparison to the untreated side (Figure 2E, F, Supplementary
391 Table 4).

392

393 Supportive biomarkers

394 We investigated biological pathways impacted by topical UA application for a period of 8 weeks
395 by performing RNA-seq transcriptomics of forearm skin biopsies from the *aging study 1*. Gene
396 set enrichment analysis (GSEA) was applied to identify significant pathways changed by UA
397 comparing samples at the study end to baseline and normalizing results over vehicle. “Collagen
398 fibril organization” was the molecular pathway most significantly activated by UA (Fig. 3A and

399 Suppl. Fig. 3A), with UA application also reducing gene sets related to chemokine response (Fig.
400 3A). We further studied which UA regulated pathways are involved in the natural skin aging
401 process. Analysing a publicly available skin aging clinical study ¹³, the “Collagen fibril
402 organization” was a common signature, both induced by UA and downregulated with skin aging
403 (Suppl. Fig. 3B). This gene set includes collagen genes encoding for fibrillar type I and III
404 collagen (Fig. 3B), known to decline in skin with chronological aging ¹⁴, photo-aging and
405 smoking ¹⁵. UA also upregulated age-associated decline of genes involved in skin homeostasis.
406 Among them, *EMILIN-1*, regulating 3D structure and elasticity ¹⁶ and *AEBP*, encoding for a
407 collagen-interacting protein required for optimal tissue repair ¹⁷ (Fig. 3B). These data provide
408 mechanistic insight into the positive impact of UA on wrinkle reduction, a process that is driven
409 by impaired collagen production and organization in the skin. The GSEA results reveals insights
410 on the impact of UA on the dermis, the skin layer producing and secreting collagen.
411 To better understand the mechanisms of action of UA in dermal cells, we treated primary human
412 dermal fibroblasts with UA at either 2.5 μ M or 10 μ M, or with vehicle, for 24 hours.
413 Surprisingly, this short-term exposure to UA did not alter collagen gene expression (Suppl. Fig.
414 3C). However, it suppressed the expression of the gene involved in collagen degradation, Matrix
415 Metalloproteinases (*MMP1*) (Fig. 3C). Moreover, UA induced a dose-dependent increase in the
416 expression of the mitophagy genes *PARKIN* and *PINK1* and the autophagy genes *MAP1LC3* and
417 *ULK1*, compared to vehicle-treated cells (Fig. 3C).
418 Human primary keratinocytes treated with UA or vehicle for 24 hours showed a similar gene
419 expression signature as dermal cells. UA led to a significant downregulation of both *MMP1* and
420 the other key collagen degrading enzyme, *MMP3* (Fig. 3D), and it upregulated autophagy and
421 mitophagy gene expression, as in dermal fibroblasts (Fig. 3D). Finally, we employed a model of
422 3D reconstituted human epidermis (RHE) applied daily with the UA 1% moisturizing cream for
423 3 days. No change was observed in *MMP1* and *MMP3* gene expression (Suppl. Fig 3D), however,
424 consistent with the data in primary cells, an early activation of mitophagy and autophagy genes
425 in RHE applied with UA compared to Vehicle in the RHE model (Fig. 3E).
426

427 **Photodamage study**

428 *Efficacy*

429 In the *photodamage study* all erythema (a*)-values measured 24 hours after irradiation were
430 higher than at baseline for all treatment codes, indicating the development of a sunburn on all the
431 tested areas. The chromameter measurements showed significantly less skin redness (erythema)
432 for 1 % UA treated group after UV exposure at the 1.6MED dose in comparison to the respective
433 untreated area (-13%, $p=0.02$; Figure 4A), whereas neither the lower concentration with 0.5%
434 (data not shown) nor the placebo showed a significant effect compared to the untreated control.

435

436 *Supportive Biomarkers*

437 The clinical data from the *photodamage study* supports a protective effect of UA against UV
438 irradiation induced skin damage. We used the RHE to investigate whether this was associated
439 with reduction in the reduction of detrimental inflammation generated by UV irradiation. RHE
440 were applied topically with either the basal topical formulation or a formulation containing UA
441 at 1%. After 24 hours of incubation, RHE tissues were exposed to UVB irradiation and then
442 incubated with the same topical formulations for an additional 24 hours. A group of RHE were
443 left untreated and non-irradiated as negative controls. We measured the concentration of
444 prostaglandin G2 (PGE2) in the culture supernatant, as biomarker of inflammation. Irradiated
445 RHE showed significant increase in PGE2 release compared to non-irradiated tissues (Fig. 4B).
446 UA 1% application of irradiated RHE significantly reduced PGE2 levels, indicating an anti-
447 inflammatory action or the active (Fig. 4B).

448

449

450

451

452

453

454

455

456 Discussion

457 Measures to protect against skin aging are essential for maintaining healthy, youthful-looking
458 skin and reducing the risk of skin damage and diseases. In this set of clinical studies, we showed
459 that topical application of skincare products containing UA significantly counteract both natural
460 intrinsic cellular aging and extrinsic photoaging. We performed three complementary
461 randomized clinical studies to document both safety and efficacy of topically applied UA on the
462 skin of healthy adult subjects. Safety was confirmed by a lack of any serious side effects in all
463 participants. In addition, a human-repeat insult patch test conducted (in n=109 subjects,
464 NCT05079607) prior to the start of these randomized trials revealed no irritant or sensitization
465 potential of UA on human skin (data not shown).

466
467 Efficacy of the active UA was observed both when applied alone in a basal topical cream
468 formulation (*aging study 1*) and when applied in a day, night cream or serum matrix with a
469 calibrated dose of UA (*aging study 2*). Skin wrinkles are a hallmark of skin aging, especially on
470 facial skin and are known to contribute to the overall rate of aging by inducing oxidative stress
471 and via skin cells that acquire a pro-inflammatory state. Skin wrinkles in the crow's feet area
472 around the eyes were significantly reduced by an 8-week daily application of UA in multiple
473 skin cream matrices (basal cream formulation, a day-cream, a night cream and serum all
474 containing the same dose of 1% UA). This effect was visible as early as 2-weeks after topical
475 application in all the studies and with the different formulations (Supplementary Table xx). At
476 the molecular level, a hallmark of skin aging is the decline in content and organization of
477 collagen and the extracellular matrix, which provides structural support within the skin tissue.
478 Our data from unbiased skin biopsy RNA-sequencing, showed that topical application of
479 urolithin A increases the expression of the same collagen proteins down-regulated upon natural
480 aging. Further mechanistic analysis in primary human cells and in 3D human skin models
481 revealed that short-term exposure to UA increased mitophagy and autophagy related genes. This
482 is consistent with the molecular signature previously shown in several preclinical models and in
483 human clinical studies in the skeletal muscle. In the same skin models, UA also significantly
484 reduced expression of enzymes causing collagen degradation.

485 In addition to the protective effects of UA on intrinsic cellular aging, we provide evidence that
486 UA topical application counteracts photoaging. The exposure of excessive UVB radiation from
487 sun is linked to increased skin oxidative stress and an acceleration of skin tissue aging. UA was
488 already shown to protect against UVB-induced photoaging in 2D human dermal fibroblasts,
489 through the activation of mitophagy¹⁸. In the current report, we demonstrate for the first time in
490 humans that topically applied UA, in a randomized, double-blind trial, protects against UVB
491 exposed skin, with effects observed following a little as 24-hours after UV exposure that was
492 equivalent to a moderate sunburn. We demonstrated the active UA doses required to significantly
493 reduce UVB irradiation induced erythema formation. Employing a 3D human skin model to
494 investigate mechanistic benefits of UA, we observed a reduced production of prostaglandin E2
495 (PGE2), a pro-inflammatory molecule induced by UV irradiation.

496
497 Compared to UA, other actives employed to counter skin aging have either a less favourable
498 safety profile or more limited range of beneficial effects. Retinol is a commonly used active
499 known to increase collagen production, reduce fine lines, wrinkles and to improve photoaging
500^{5,19}. However, retinol increases cell turnover in skin, which results in peeling and dry and flaky
501 effect on skin. It has been shown to cause a dose dependent irritation and erythema with repeated
502 use²⁰. In addition, retinol gets degraded on exposure to light and air²¹.

503
504 There are limited interventions to counteract the effects of both skin natural aging that leads to
505 wrinkle reduction and photoaging, without undesirable side effects. In these randomized clinical
506 studies, across ~180 subjects, topical application of the natural compound UA was shown to be
507 safe and achieved statistically significant improvement in the signs of both intrinsic aging
508 (wrinkle reduction) and extrinsic aging, i.e., UVB-induced photodamage (erythema) in healthy
509 subjects. The benefits were associated with the modulation of collagen and mitochondrial related
510 pathways that contribute to the skin aging processes. Taken together, these results show that UA
511 is a safe and effective natural intervention to counteract skin aging.

512
513
514

515 **Author Contributions**

516 A.S., C.R. and D.D. contributed to the design of the study. A.S. oversaw the clinical study
517 conduct and operations. N.H. and M.B. coordinated on-site clinical study execution and sample
518 collection as Principal investigators; D.D. oversaw the biomarkers analyses. A.M.F. performed
519 sample processing, and cell-based experiments. A.F., D.D. analyzed the ex-vivo data. D.K.,
520 performed all bioinformatic analyses. D.D., J.F., C.R., and A.S. interpreted the data and wrote
521 the manuscript, with the help of the other co-authors. All authors reviewed the manuscript.

522

523 **Conflict of Interest Disclosures**

524 The authors declare the following competing interests: D.D., A.M.F., J.F., C.R. and A.S., are
525 employees of Amazentis SA, who is the sponsor of this clinical study.

526

527 **Acknowledgement**

528 The authors would like to thank all the study participants for their involvement in the different
529 clinical studies.

530

531

532

533

534

535

536

537

538

539

540

541 **Figure Legends**

542 **Figure 1. CONSORT Diagram of Aging Study 1** 55 Participants were screened in the placebo-
543 controlled, first aging study of which n=48 middle aged women subject with mean age of $58.6 \pm$
544 6.6 years were randomized to two study arms with a split-face/arm study design with a lower
545 dose active group compared to placebo and a second higher dose active group compared to
546 placebo. Skin biopsies were conducted on the volar forearm in adjacent areas at the start and end
547 of the 8-week intervention. All participants completed the trial and were included in the final
548 analysis.

549

550 **Figure 2. Topical application of UA leads to wrinkle reduction effect**

551 UA 1% topically applied in a basic skin cream (A) in the *aging study 1* or in a more defined
552 matrix of day (B) and night (C) skin cream formulations from the *aging study 2*, exhibited
553 significant anti-wrinkle effects in middle-aged subjects with moderate facial wrinkles after 8-
554 weeks of topical application ($p < 0.05$). Skin barrier function remained healthy and unchanged
555 over the course of the *aging study 1* (D). Skin hydration was improved upon topical application
556 of different UA containing creams in *aging study 2* (E, F).

557

558 **Figure 3. UA positively impacts biomarkers associated with improved skin health (A)**

559 GSEA results from RNA-seq in skin biopsies from *aging study 1* showing the most significant
560 Gene Ontology Biological Processes (GO-BP) pathways that are significantly enriched in UA
561 compared to vehicle. Terms with positive and negative normalized enrichment scores (NES), are
562 categorized as “activated” and “suppressed”, respectively. Pathways are sorted by gene ratio, dot
563 sizes scaled by the number of core enriched genes, and dot color reflects the statistical
564 significance of the enrichment (Benjamini-Hochberg-adjusted p-value, P-adj). (B) Bar plot
565 showing increased expression in core genes of the “Collagen fibril organization” pathway in skin
566 biopsies exposed to UA compared to the vehicle group (top). Bar plot of Aging Beta value for
567 same genes derived from the skin aging trial (bottom). Only common core enriched genes
568 between UA and skin aging dataset are shown. (C-D) Expression of genes encoding for collagen
569 degrading enzymes (*MMP1*, *MMP3*) and autophagy/mitophagy proteins (*PINK1*, *PARK2*,
570 *SQSTM1*, *ULK1*) in human dermal fibroblasts (C) and human keratinocytes (D) treated for 24

571 hours with DMSO or the indicated doses of UA. **(E)** Expression of genes encoding for
572 autophagy/mitophagy proteins (*PINK1*, *PARK2*, *SQSTM1*, *ULK1*) in human reconstituted
573 epidermis after daily application for 72 hours of Vehicle or UA 1% containing moisturizers. Data
574 expressed as Fold change over Vehicle +/- sem. *p< 0.05; **P < 0.01; ***P < 0.005; ***P <
575 0.001 One-Way ANOVA.

576

577 **Figure 4. (A). (B)** Levels of prostaglandin E2 (PGE2) secreted in the media of 3D reconstituted
578 human epidermis in the indicated experimental conditions. Data expressed as Fold change over
579 Vehicle +/- sem. *p< 0.05; ***P < 0.005. One-Way ANOVA.

580

581

582 **Supplementary Figure Legends**

583 **Supplementary Figure 1.** CONSORT Flow Diagram for (A) *Aging Study 2* and (B) UVB-
584 induced Erythema, *Photodamage Trial*

585

586 **Supplementary Figure 2. Impact of Mitopure on biomarkers associated with improved skin**
587 **health**

588 **(A)** Heatmap of log₂ fold changes from core enriched genes of the “Collagen fibril organization”
589 pathway comparing end of study to baseline, in UA skin biopsies after normalization over
590 vehicle controls. Only subjects present in both visits and both treatments are considered in
591 visualization. Rows (genes) were hierarchically clustered with a Euclidean distance metric using
592 complete linkage. **(B)** Normalized enrichment score (NES) of “Collagen fibril organization”
593 pathway for UA normalized over vehicle comparison and for the “aging” dataset. The
594 significance level of the BP enrichment for each comparison/dataset is denoted accordingly. **(C)**
595 Expression of the gene encoding for Collagen Type I Alpha 1 Chain (*COL1A1*) in human dermal
596 fibroblasts treated for 24 hours with DMSO or the indicated doses of Mitopure. **(D)** Expression
597 of genes encoding for collagen degrading enzymes (*MMP1*, *MMP3*) in human reconstituted
598 epidermis after daily application for 72 hours of Vehicle or Mitopure 1% containing moisturizer.
599 Data expressed as Fold change over Vehicle +/- sem.

600 **References**

- 601 1. Pandel R, Poljšak B, Godic A, Dahmane R. Skin photoaging and the role of antioxidants in
602 its prevention. *ISRN Dermatol.* 2013;2013:930164. doi:10.1155/2013/930164
- 603 2. Baumann L. Skin ageing and its treatment. *J Pathol.* 2007;211(2):241-251.
604 doi:10.1002/path.2098
- 605 3. Farage MA, Miller KW, Elsner P, Maibach HI. Structural characteristics of the aging skin: a
606 review. *Cutan Ocul Toxicol.* 2007;26(4):343-357. doi:10.1080/15569520701622951
- 607 4. Pilkington SM, Bulfone-Paus S, Griffiths CEM, Watson REB. Inflammaging and the Skin. *J*
608 *Invest Dermatol.* 2021;141(4S):1087-1095. doi:10.1016/j.jid.2020.11.006
- 609 5. Kafi R, Kwak HSR, Schumacher WE, et al. Improvement of naturally aged skin with vitamin
610 A (retinol). *Arch Dermatol.* 2007;143(5):606-612. doi:10.1001/archderm.143.5.606
- 611 6. Mariwalla K. SUPPLEMENT ARTICLE: Effectiveness of Retinol for Skin Health. *J Drugs*
612 *Dermatol.* 2022;21(7):s3. doi:10.36849/JDD.0722
- 613 7. D'Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J. Impact of the Natural
614 Compound Urolithin A on Health, Disease, and Aging. *Trends Mol Med.* 2021;27(7):687-
615 699. doi:10.1016/j.molmed.2021.04.009
- 616 8. Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle
617 Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. *JAMA*
618 *Netw Open.* 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279
- 619 9. Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise
620 performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged
621 adults. *Cell Rep Med.* 2022;3(5):100633. doi:10.1016/j.xcrm.2022.100633
- 622 10. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-
623 based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.*
624 2005;102(43):15545-15550. doi:10.1073/pnas.0506580102

- 625 11. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological
626 Themes Among Gene Clusters. *OMICS: A Journal of Integrative Biology*. 2012;16(5):284-
627 287. doi:10.1089/omi.2011.0118
- 628 12. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology.
629 The Gene Ontology Consortium. *Nat Genet*. 2000;25(1):25-29. doi:10.1038/75556
- 630 13. Glass D, Viñuela A, Davies MN, et al. Gene expression changes with age in skin, adipose
631 tissue, blood and brain. *Genome Biol*. 2013;14(7):R75. doi:10.1186/gb-2013-14-7-r75
- 632 14. Varani J, Dame MK, Rittie L, et al. Decreased collagen production in chronologically aged
633 skin: roles of age-dependent alteration in fibroblast function and defective mechanical
634 stimulation. *Am J Pathol*. 2006;168(6):1861-1868. doi:10.2353/ajpath.2006.051302
- 635 15. Knuutinen A, Kokkonen N, Risteli J, et al. Smoking affects collagen synthesis and
636 extracellular matrix turnover in human skin. *Br J Dermatol*. 2002;146(4):588-594.
637 doi:10.1046/j.1365-2133.2002.04694.x
- 638 16. Fitoussi R, Beauchef G, Guéré C, André N, Vié K. Localization, fate and interactions of
639 Emilin-1 in human skin. *Int J Cosmet Sci*. 2019;41(2):183-193. doi:10.1111/ics.12524
- 640 17. Blackburn PR, Xu Z, Tumelty KE, et al. Bi-allelic Alterations in AEBP1 Lead to Defective
641 Collagen Assembly and Connective Tissue Structure Resulting in a Variant of Ehlers-Danlos
642 Syndrome. *Am J Hum Genet*. 2018;102(4):696-705. doi:10.1016/j.ajhg.2018.02.018
- 643 18. Liu W, Yan F, Xu Z, et al. Urolithin A protects human dermal fibroblasts from UVA-
644 induced photoaging through NRF2 activation and mitophagy. *J Photochem Photobiol B*.
645 2022;232:112462. doi:10.1016/j.jphotobiol.2022.112462
- 646 19. Pisetpackdeekul P, Supmuang P, Pan-In P, et al. Proretinal nanoparticles: stability, release,
647 efficacy, and irritation. *Int J Nanomedicine*. 2016;11:3277-3286. doi:10.2147/IJN.S111748
- 648 20. Milosheska D, Roškar R. Use of Retinoids in Topical Antiaging Treatments: A Focused
649 Review of Clinical Evidence for Conventional and Nanoformulations. *Adv Ther*.
650 2022;39(12):5351-5375. doi:10.1007/s12325-022-02319-7

- 651 21. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the
652 treatment of skin aging: an overview of clinical efficacy and safety. *Clin Interv Aging*.
653 2006;1(4):327-348. doi:10.2147/ciia.2006.1.4.327
- 654 22. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and
655 pharmacokinetics. *Free Radic Res*. 2006;40(5):445-453. doi:10.1080/10715760600617843
- 656 23. Inui M, Ooe M, Fujii K, Matsunaka H, Yoshida M, Ichihashi M. Mechanisms of inhibitory
657 effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. *Biofactors*.
658 2008;32(1-4):237-243. doi:10.1002/biof.5520320128
- 659




Figure 1









Figure 2










Figure 3

A**B**